[go: up one dir, main page]

WO2025096487A1 - Composés de type protéase 1 spécifique de l'ubiquitine (usp1) - Google Patents

Composés de type protéase 1 spécifique de l'ubiquitine (usp1) Download PDF

Info

Publication number
WO2025096487A1
WO2025096487A1 PCT/US2024/053489 US2024053489W WO2025096487A1 WO 2025096487 A1 WO2025096487 A1 WO 2025096487A1 US 2024053489 W US2024053489 W US 2024053489W WO 2025096487 A1 WO2025096487 A1 WO 2025096487A1
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
alkyl
formula
alkynyl
alkenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/053489
Other languages
English (en)
Inventor
Yanting Huang
Khehyong Ngu
Wei Meng
David R. Tortolani
Anirudra PAUL
Murali T.G. Dhar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of WO2025096487A1 publication Critical patent/WO2025096487A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Definitions

  • UBIQUITIN SPECIFIC PROCESSING PROTEASE 1 (USP1) COMPOUNDS CROSS REFERENCE TO RELATED APPLICATIONS
  • USP1 UBIQUITIN SPECIFIC PROCESSING PROTEASE 1
  • USP1 COMPOUNDS CROSS REFERENCE TO RELATED APPLICATIONS
  • This application claims the benefit of U.S. Provisional Application No. 63/594,446, filed, October 31, 2023, the entire content of which is hereby incorporated herein by reference.
  • FIELD This invention relates to compounds which are inhibitors of ubiquitin-specific- processing protease 1 (USP1) useful for treating diseases including, among others, cancer, autoimmune and inflammatory disorders.
  • the invention further pertains to pharmaceutical compositions containing at least one compound according to the invention that are useful for the treatment of conditions related to the inhibition of USP1 in a mammal.
  • Ubiquitination is important in the regulation of many cellular functions and cellular homeostasis.
  • the conjugation of ubiquitin to a target protein is a multistep process involving the sequential action of a ubiquitin activating enzyme (E1), a ubiquitin- conjugating enzyme (E2), and a ubiquitin protein-ligase (E3).
  • E1 ubiquitin activating enzyme
  • E2 ubiquitin- conjugating enzyme
  • E3 ubiquitin protein-ligase
  • the ubiquitin tags can mediate non-covalent interactions of the ubiquitinated substrate with other proteins bearing different types of ubiquitin-binding motifs.
  • a family of enzymes, termed deubiquitinases act on ubiquitinated substrates to catalyze the removal of ubiquitin moieties.
  • USP1 ubiquitin-specific protease 1
  • USP1 is a regulator of several important steps in the DNA damage response, particularly in the Fanconi anemia pathway, and in the process of translesion synthesis. USP1 has also been reported to contribute to the repair of double-strand DNA breaks through homologous recombination. In addition, USP1 has been reported to deubiquitinate and stabilize members of the family of inhibitors of DNA binding (ID) proteins, ID1, ID2 and ID3.
  • ID DNA binding
  • the present disclosure provides compounds that modulate the expression or activity of USP1.
  • the disclosure also provides compositions, including pharmaceutical compositions, kits that include the compounds, and methods of using (or administering) and making the compounds.
  • the compounds provided herein are useful in treating diseases, disorders, or conditions that are mediated by USP1.
  • the disclosure also provides compounds for use in therapy.
  • the disclosure further provides compounds for use in a method of treating a disease, disorder, or condition that is mediated by USP1.
  • the disclosure provides uses of the compounds in the manufacture of a medicament for the treatment of a disease, disorder or condition that is mediated by (or mediated, at least in part, by) USP1.
  • n 0, 1, 2 or 3
  • R 1 is selected from C6 aryl and 5-6 membered heteroaryls, optionally substituted with one to four halo, hydroxy, amino, -C(O)R a , -C(O)OR b , -C(O)NR a R b , -N(R a )C(O)R b , - S(O)NR a R b , -S(O)2NR a R b , -S(O)R g , -S(O)2R g , -NR a R b , -OR a , -SR b , C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl and C3-8 cycloalkyl; wherein each C1-6 alkyl
  • pharmaceutical compositions comprising a pharmaceutically acceptable carrier and at least one of the compounds disclosed herein.
  • the present application also provides methods for the inhibition of USP1 comprising administering a therapeutically effective amount of at least one of Formula I.
  • the present application also provides a method for treating proliferative, metabolic, allergic, autoimmune and inflammatory diseases, comprising administering to a host in need of such treatment a therapeutically effective amount of at least one of the compounds disclosed herein.
  • the compounds of Formula I or a pharmaceutically acceptable salt thereof may be used to treat cancers that are mediated by, dependent on or associated with USP1 activity.
  • the disease is a solid tumor.
  • n 0, 1, 2 or 3
  • R 1 is selected from C 6 aryl and 5-6 membered heteroaryls, optionally substituted with one to four halo, hydroxy, amino, -C(O)R a , -C(O)OR b , -C(O)NR a R b , -N(R a )C(O)R b , - S(O)NR a R b , -S(O)2NR a R b , -S(O)R g , -S(O)2R g , -NR a R b , -OR a , -SR b , C1-6 alkyl, C2-6 alkenyl, C 2-6 alkyny
  • R 1 is: or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers thereof.
  • R 2 is selected from: absent, -H and -CH 3 , or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or deuterated analog thereof.
  • the compounds described herein e.g., a compound of Formula I, II, IIIa, IIIb, IIIc or IIId, IIIe, IIIf, IVa, IVb, V, VI, VIIa, VIIb, VIIIa, VIIIb, IXa, IXb or Table A
  • the disease is a solid tumor.
  • the solid tumor is selected from prostate cancer, pancreatic cancer, bladder cancer, colorectal cancer, breast cancer, renal cancer, hepatocellular cancer, lung cancer, ovarian cancer, cervical cancer, gastric cancer, esophageal cancer, head and neck cancer, melanoma, neuroendocrine cancers, CNS cancers, brain tumors (e.g., glioma, anaplastic oligodendroglioma, adult glioblastoma multiforme, and adult anaplastic astrocytoma), bone cancer, or soft tissue sarcoma.
  • the solid tumor is from non-small cell lung cancer or small-cell lung cancer.
  • Cis- and trans-geometric isomers of the compounds of the present invention are described and may be isolated as a mixture of isomers or as separated isomeric forms.
  • the present compounds can be isolated in optically active or racemic forms. It is well known in the art how to prepare optically active forms, such as by resolution of racemic forms or by synthesis from optically active starting materials. All chiral, (enantiomeric and diastereomeric) and racemic forms and all geometric isomeric forms of a structure are intended, unless the specific stereochemistry or isomer form is specifically indicated.
  • any variable e.g., R 3
  • its definition at each occurrence is independent of its definition at every other occurrence.
  • a group may optionally be substituted with up to two R 3 groups and R 3 at each occurrence is selected independently from the definition of R 3 .
  • R 3 at each occurrence is selected independently from the definition of R 3 .
  • combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.
  • a bond to a substituent is shown to cross a bond connecting two atoms in a ring, then such substituent may be bonded to any atom on the ring.
  • substituent When a substituent is listed without indicating the atom via which such substituent is bonded to the rest of the compound of a given formula, then such substituent may be bonded via any atom in such substituent.
  • a dash "-" that is not between two letters or symbols is used to indicate a point of attachment for a substituent. For example, -CONH2 is attached through the carbon atom.
  • a dash at the front or end of a chemical group is a matter of convenience; chemical groups may be depicted with or without one or more dashes without losing their ordinary meaning.
  • a wavy line drawn through a line in a structure indicates a point of attachment of a group. Unless chemically or structurally required, no directionality is indicated or implied by the order in which a chemical group is written or named.
  • optionally substituted in reference to a particular moiety of the compound of Formula I (e.g., an optionally substituted heteroaryl group) refers to a moiety having 0, 1, 2, or more substituents.
  • optionally substituted alkyl encompasses both “alkyl” and “substituted alkyl” as defined below. It will be understood by those skilled in the art, with respect to any group containing one or more substituents, that such groups are not intended to introduce any substitution or substitution patterns that are sterically impractical, synthetically non-feasible and/or inherently unstable.
  • the term “at least one chemical entity” is interchangeable with the term "a compound”.
  • C u-v indicates that the following group has from u to v carbon atoms.
  • C 1-6 alkyl indicates that the alkyl group has from 1 to 6 carbon atoms.
  • alkyl or alkylene is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms.
  • C 1-10 alkyl (or alkylene), is intended to include C 1 , C 2 , C 3 , C 4 , C5, C6, C7, C8, C9, and C10 alkyl groups.
  • C1-C6 alkyl denotes alkyl having 1 to 6 carbon atoms.
  • Alkyl groups can be unsubstituted or substituted so that one or more of its hydrogens are replaced by another chemical group.
  • Example alkyl groups include, but are not limited to, methyl (Me), ethyl (Et), propyl (e.g., n-propyl and isopropyl), butyl (e.g., n-butyl, isobutyl, t-butyl), pentyl (e.g., n-pentyl, isopentyl, neopentyl), and the like.
  • alkenyl or “alkenylene” is intended to include hydrocarbon chains of either straight or branched configuration and having one or more double carbon-carbon bonds that may occur in any stable point along the chain.
  • C2-6 alkenyl (or alkenylene), is intended to include C 2 , C 3 , C 4 , C 5 , and C 6 alkenyl groups.
  • alkenyl examples include, but are not limited to, ethenyl, 1-propenyl, 2-propenyl, 2-butenyl, 3-butenyl, 2-pentenyl, 3- pentenyl, 4-pentenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 2-methyl-2-propenyl, 4- methyl-3-pentenyl, and the like.
  • alkynyl or “alkynylene” is intended to include hydrocarbon chains of either straight or branched configuration and having one or more triple carbon-carbon bonds that may occur in any stable point along the chain.
  • C2-6 alkynyl (or alkynylene), is intended to include C 2 , C 3 , C 4 , C 5 , and C 6 alkynyl groups; such as ethynyl, propynyl, butynyl, pentynyl, hexynyl and the like.
  • CO2 the designation
  • alkyl is used together with another group, such as in “arylalkyl"
  • this conjunction defines with more specificity at least one of the substituents that the substituted alkyl will contain.
  • arylalkyl refers to a substituted alkyl group as defined above where at least one of the substituents is an aryl, such as benzyl.
  • aryl(C0-4)alkyl includes a substituted lower alkyl having at least one aryl substituent and also includes an aryl directly bonded to another group, i.e., aryl(C 0 )alkyl.
  • heteroarylalkyl refers to a substituted alkyl group as defined above where at least one of the substituents is a heteroaryl.
  • alkenyl, alkynyl, alkylene, alkenylene, or alkynylene group these groups are substituted with one to three substituents as defined above for substituted alkyl groups.
  • alkoxy refers to an oxygen atom substituted by alkyl or substituted alkyl, as defined herein.
  • alkoxy includes the group -O-C 1-6 alkyl such as methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy, pentoxy, 2-pentyloxy, isopentoxy, neopentoxy, hexoxy, 2-hexoxy, 3-hexoxy, 3- methylpentoxy, and the like.
  • Lower alkoxy refers to alkoxy groups having one to four carbons.
  • cycloalkyl refers to cyclized alkyl groups, including mono-, bi- or poly- cyclic ring systems.
  • C 3-7 cycloalkyl is intended to include C 3 , C 4 , C 5 , C 6 , and C 7 cycloalkyl groups.
  • Example cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, norbornyl, and the like.
  • “carbocycle” or “carbocyclic residue” is intended to mean any stable 3-, 4-, 5-, 6-, or 7-membered monocyclic or bicyclic or 7-, 8-, 9-, 10-, 11-, 12-, or 13-membered bicyclic or tricyclic ring, any of which may be saturated, partially unsaturated, unsaturated or aromatic.
  • carbocycles include, but are not limited to, cyclopropyl, cyclobutyl, cyclobutenyl, cyclopentyl, cyclopentenyl, cyclohexyl, cycloheptenyl, cycloheptyl, cycloheptenyl, adamantyl, cyclooctyl, cyclooctenyl, cyclooctadienyl, [3.3.0]bicyclooctane, [4.3.0]bicyclononane, [4.4.0]bicyclodecane, [2.2.2]bicyclooctane, fluorenyl, phenyl, naphthyl, indanyl, adamantyl, anthracenyl, and tetrahydronaphthyl (tetralin).
  • bridged rings are also included in the definition of carbocycle (e.g., [2.2.2]bicyclooctane).
  • carbocycles e.g., [2.2.2]bicyclooctane
  • Preferred carbocycles are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and phenyl.
  • carbocycle When the term “carbocycle” is used, it is intended to include “aryl”.
  • a bridged ring occurs when one or more carbon atoms link two non-adjacent carbon atoms.
  • Preferred bridges are one or two carbon atoms. It is noted that a bridge always converts a monocyclic ring into a bicyclic ring.
  • aryl refers to monocyclic or bicyclic aromatic hydrocarbon groups having 6 to 12 carbon atoms in the ring portion, such as phenyl, and naphthyl groups, each of which may be substituted.
  • cycloalkyl includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, bicyclooctyl, etc., as well as the following ring systems: , and the like, which optionally may be substituted at any available atoms of the ring(s).
  • halo or “halogen” refers to chloro, bromo, fluoro and iodo.
  • haloalkyl means a substituted alkyl having one or more halo substituents.
  • haloalkyl includes mono, bi, and trifluoromethyl.
  • haloalkoxy means an alkoxy group having one or more halo substituents.
  • haloalkoxy includes OCF3.
  • heterocycle refers to substituted and unsubstituted 3- to 7-membered monocyclic groups, 7- to 11-membered bicyclic groups, and 10- to 15- membered tricyclic groups, in which at least one of the rings has at least one heteroatom (O, S or N), said heteroatom containing ring preferably having 1, 2, or 3 heteroatoms selected from O, S, and N.
  • Each ring of such a group containing a heteroatom can contain one or two oxygen or sulfur atoms and/or from one to four nitrogen atoms provided that the total number of heteroatoms in each ring is four or less, and further provided that the ring contains at least one carbon atom.
  • the nitrogen and sulfur atoms may optionally be oxidized and the nitrogen atoms may optionally be quaternized.
  • the fused rings completing the bicyclic and tricyclic groups may contain only carbon atoms and may be saturated, partially saturated, or fully unsaturated.
  • the heterocyclo group may be attached at any available nitrogen or carbon atom.
  • heterocycle As used herein the terms “heterocycle”, “heterocycloalkyl”, “heterocyclo”, “heterocyclic”, and “heterocyclyl” include “heteroaryl” groups, as defined below.
  • exemplary monocyclic heterocyclyl groups include azetidinyl, pyrrolidinyl, oxetanyl, imidazolinyl, oxazolidinyl, isoxazolinyl, thiazolidinyl, isothiazolidinyl, tetrahydrofuranyl, piperidyl, piperazinyl, 2- oxopiperazinyl, 2-oxopiperidyl, 2-oxopyrrolodinyl, 2-oxoazepinyl, azepinyl, 1-pyridonyl, 4-piperidonyl, tetrahydropyranyl, morpholinyl, thiamorpholinyl
  • heteroaryl refers to substituted and unsubstituted aromatic 5- or 6- membered monocyclic groups, 9- or 10-membered bicyclic groups, and 11- to 14- membered tricyclic groups which have at least one heteroatom (O, S or N) in at least one of the rings, said heteroatom-containing ring preferably having 1, 2, or 3 heteroatoms selected from O, S, and N.
  • Each ring of the heteroaryl group containing a heteroatom can contain one or two oxygen or sulfur atoms and/or from one to four nitrogen atoms provided that the total number of heteroatoms in each ring is four or less and each ring has at least one carbon atom.
  • the fused rings completing the bicyclic and tricyclic groups may contain only carbon atoms and may be saturated, partially saturated, or unsaturated.
  • the nitrogen and sulfur atoms may optionally be oxidized and the nitrogen atoms may optionally be quaternized.
  • Heteroaryl groups which are bicyclic or tricyclic must include at least one fully aromatic ring but the other fused ring or rings may be aromatic or non- aromatic.
  • Exemplary monocyclic heteroaryl groups include pyrrolyl, pyrazolyl, pyrazolinyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl, isothiazolyl, furanyl, thienyl, oxadiazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl and the like.
  • Exemplary bicyclic heteroaryl groups include indolyl, benzothiazolyl, benzodioxolyl, benzoxazolyl, benzothienyl, quinolinyl, tetrahydroisoquinolinyl, isoquinolinyl, benzimidazolyl, benzopyranyl, indolizinyl, benzofuranyl, chromonyl, coumarinyl, benzopyranyl, cinnolinyl, quinoxalinyl, indazolyl, pyrrolopyridyl, furopyridyl, dihydroisoindolyl, tetrahydroquinolinyl and the like.
  • Exemplary tricyclic heteroaryl groups include carbazolyl, benzindolyl, phenanthrollinyl, acridinyl, phenanthridinyl, xanthenyl and the like.
  • preferred heteroaryl groups include: the like, which optionally may be substituted at any available carbon or nitrogen atom.
  • aryl e.g., phenyl
  • cycloalkyl e.g., cyclohexyl
  • heterocyclo e.g., pyrrolidinyl, piperidinyl, and morpholinyl
  • heteroaryl e.g., tetrazolyl, imidazolyl, pyrazolyl, triazolyl, thiazolyl, and furyl
  • the reference is intended to include rings having 0 to 3, preferably 0 to 2, substituents selected from those recited above for the aryl, cycloalkyl, heterocyclo and/or heteroaryl groups, as appropriate.
  • Carbocyclyl or “carbocyclic” refers to a saturated or unsaturated monocyclic or bicyclic ring in which all atoms of all rings are carbon. Thus, the term includes cycloalkyl and aryl rings.
  • Monocyclic carbocycles have 3 to 6 ring atoms, still more typically 5 or 6 ring atoms.
  • Bicyclic carbocycles have 7 to 12 ring atoms, e.g., arranged as a bicyclo [4,5], [5,5], [5,6] or [6,6] system, or 9 or 10 ring atoms arranged as a bicyclo [5,6] or [6,6] system.
  • Examples of mono- and bicyclic carbocycles include cyclopropyl, cyclobutyl, cyclopentyl, 1-cyclopent-1-enyl, 1-cyclopent-2-enyl, 1- cyclopent-3-enyl, cyclohexyl, 1-cyclohex-1-enyl, 1-cyclohex-2-enyl, 1-cyclohex-3-enyl, phenyl and naphthyl.
  • the carbocyclic ring may be substituted in which case the substituents are selected from those recited above for cycloalkyl and aryl groups.
  • alkylthio refers to the group "alkyl-S-".
  • acyl refers to a group -C(O)R, wherein R is hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl; each of which may be optionally substituted, as defined herein.
  • R is hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl; each of which may be optionally substituted, as defined herein.
  • examples of acyl include formyl, acetyl, cylcohexylcarbonyl, cyclohexylmethyl-carbonyl, and benzoyl.
  • amido refers to both a "C-amido” group which refers to the group -- C(O)NR g R h and an "N-amido” group which refers to the group –NR g C(O)R h , wherein R g and R h are independently selected from hydrogen, alkyl, aryl, haloalkyl, or heteroaryl; each of which may be optionally substituted.
  • amino refers to the group -NR g R h wherein R g and R h are independently selected from hydrogen, alkyl, haloalkyl, aryl, or heteroaryl; each of which may be optionally substituted.
  • the term “azido” refers to –N3.
  • the term “carbamoyl” refers to both an "O-carbamoyl” group which refers to the group -O-C(O)NR i R j and an "N-carbamoyl” group which refers to the group – NR i C(O)OR j , wherein R i and R j are independently selected from hydrogen, alkyl, aryl, haloalkyl, or heteroaryl; each of which may be optionally substituted.
  • the term “carboxyl” refers to -C(O)OH.
  • Carboxyl ester refers to both -OC(O)R and -C(O)OR g , wherein R g is hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl; each of which may be optionally substituted, as defined herein.
  • cyano or “carbonitrile” refers to the group -CN.
  • cycloalkyl refers to a saturated or partially unsaturated cyclic alkyl group having a single ring or multiple rings including fused, bridged, and spiro ring systems.
  • cycloalkyl includes cycloalkenyl groups (i.e.
  • cycloalkyl has from 3 to 20 ring carbon atoms (i.e., C.sub.3-20 cycloalkyl), 3 to 12 ring carbon atoms (i.e., C.sub.3-12 cycloalkyl), 3 to 10 ring carbon atoms (i.e., C.sub.3-10 cycloalkyl), 3 to 8 ring carbon atoms (i.e., C.sub.3- 8 cycloalkyl), or 3 to 6 ring carbon atoms (i.e., C.sub.3-6 cycloalkyl).
  • cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
  • heteroatoms shall include oxygen, sulfur and nitrogen.
  • unsaturated is used herein to refer to a ring or group, the ring or group may be fully unsaturated or partially unsaturated.
  • groups and substituents thereof may be chosen by one skilled in the field to provide stable moieties and compounds and compounds useful as pharmaceutically-acceptable compounds and/or intermediate compounds useful in making pharmaceutically-acceptable compounds.
  • Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds or useful synthetic intermediates.
  • a stable compound or stable structure is meant to imply a compound that is sufficiently robust to survive isolation from a reaction mixture to a useful degree of purity, and subsequent formulation into an efficacious therapeutic agent.
  • the presently recited compounds do not contain a N-halo, S(O) 2 H, or S(O)H group.
  • the compounds described herein may exist in a free form (with no ionization) or can form salts which are also within the scope of this invention. Unless otherwise indicated, reference to an inventive compound is understood to include reference to the free form and to salts thereof.
  • salt(s) denotes acidic and/or basic salts formed with inorganic and/or organic acids and bases.
  • salt(s) may include zwitterions (inner salts), e.g., when a compound of formula I, contains both a basic moiety, such as an amine or a pyridine or imidazole ring, and an acidic moiety, such as a carboxylic acid.
  • Pharmaceutically acceptable (i.e., non-toxic, physiologically acceptable) salts are preferred, such as, for example, acceptable metal and amine salts in which the cation does not contribute significantly to the toxicity or biological activity of the salt.
  • other salts may be useful, e.g., in isolation or purification steps which may be employed during preparation, and thus, are contemplated within the scope of the invention.
  • Salts of the compounds of herein may be formed, for example, by reacting a compound described herein with an amount of acid or base, such as an equivalent amount, in a medium such as one in which the salt precipitates or in an aqueous medium followed by lyophilization.
  • Exemplary acid addition salts include acetates (such as those formed with acetic acid or trihaloacetic acid, for example, trifluoroacetic acid), adipates, alginates, ascorbates, aspartates, benzoates, benzenesulfonates, bisulfates, borates, butyrates, citrates, camphorates, camphorsulfonates, cyclopentanepropionates, digluconates, dodecylsulfates, ethanesulfonates, fumarates, glucoheptanoates, glycerophosphates, hemisulfates, heptanoates, hexanoates, hydrochlorides (formed with hydrochloric acid), hydrobromides (formed with hydrogen bromide), hydroiodides, 2- hydroxyethanesulfonates, lactates, maleates (formed with maleic acid), methanesulfonates (formed with methanesul
  • Exemplary basic salts include ammonium salts, alkali metal salts such as sodium, lithium, and potassium salts; alkaline earth metal salts such as calcium and magnesium salts; barium, zinc, and aluminum salts; salts with organic bases (for example, organic amines) such as trialkylamines such as triethylamine, procaine, dibenzylamine, N-benzyl- ⁇ -phenethylamine, 1-ephenamine, N,N′-dibenzylethylene-diamine, dehydroabietylamine, N-ethylpiperidine, benzylamine, dicyclohexylamine or similar pharmaceutically acceptable amines and salts with amino acids such as arginine, lysine and the like.
  • organic bases for example, organic amines
  • trialkylamines such as triethylamine, procaine, dibenzylamine, N-benzyl- ⁇ -phenethylamine, 1-ephenamine, N,N
  • Basic nitrogen-containing groups may be quaternized with agents such as lower alkyl halides (e.g., methyl, ethyl, propyl, and butyl chlorides, bromides and iodides), dialkyl sulfates (e.g., dimethyl, diethyl, dibutyl, and diamyl sulfates), long chain halides (e.g., decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides), aralkyl halides (e.g., benzyl and phenethyl bromides), and others.
  • lower alkyl halides e.g., methyl, ethyl, propyl, and butyl chlorides, bromides and iodides
  • dialkyl sulfates e.g., dimethyl, diethyl, dibutyl, and diamyl sulfates
  • Preferred salts include monohydrochloride, hydrogensulfate, methanesulfonate, phosphate or nitrate salts.
  • the compounds described herein can be provided as amorphous solids or crystalline solids. Lyophilization can be employed to provide the compounds as a solid.
  • solvates e.g., hydrates
  • the term “solvate” means a physical association of a compound with one or more solvent molecules, whether organic or inorganic. This physical association includes hydrogen bonding. In certain instances, the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid.
  • Solidvate encompasses both solution-phase and isolable solvates.
  • Exemplary solvates include hydrates, ethanolates, methanolates, isopropanolates, acetonitrile solvates, and ethyl acetate solvates. Methods of solvation are known in the art.
  • compounds described herein subsequent to their preparation can be isolated and purified to obtain a composition containing an amount by weight equal to or greater than 99% of a compound (“substantially pure”), which is then used or formulated as described herein. Such “substantially pure” compounds described herein are also contemplated herein as part of the present invention.
  • pharmaceutically acceptable refers to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
  • pharmaceutically acceptable salts refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof. Examples of pharmaceutically-acceptable salts include, but are not limited to, mineral or organic acid salts of basic groups such as amines; and alkali or organic salts of acidic groups such as carboxylic acids.
  • the pharmaceutically-acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids.
  • such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, and nitric; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, and isethionic, and the like.
  • the pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods.
  • such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred.
  • nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred.
  • Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 18th Edition, Mack Publishing Company, Easton, PA (1990), the disclosure of which is hereby incorporated by reference.
  • “Stable compound” and “stable structure” are meant to indicate a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.
  • the present invention is intended to embody stable compounds.
  • “Therapeutically effective amount” is intended to include an amount of a compound of the present invention alone or an amount of the combination of compounds claimed or an amount of a compound of the present invention in combination with other active ingredients effective to act as an inhibitor of USP1, or effective to treat or prevent proliferative disorders, such as cancer.
  • treating cover the treatment of a disease-state in a mammal, particularly in a human, and include: (a) preventing the disease-state from occurring in a mammal, in particular, when such mammal is predisposed to the disease- state but has not yet been diagnosed as having it; (b) inhibiting the disease-state, i.e., arresting its development; and/or (c) relieving the disease-state, i.e., causing regression of the disease state. All stereoisomers of the compounds of the instant invention are contemplated, either in admixture or in pure or substantially pure form.
  • Stereoisomers may include compounds which are optical isomers through possession of one or more chiral atoms, as well as compounds which are optical isomers by virtue of limited rotation about one or more bonds (atropisomers).
  • the definition of compounds according to the invention embraces all the possible stereoisomers and their mixtures. It very particularly embraces the racemic forms and the isolated optical isomers having the specified activity.
  • the racemic forms can be resolved by physical methods, such as, for example, fractional crystallization, separation or crystallization of diastereomeric derivatives or separation by chiral column chromatography.
  • the individual optical isomers can be obtained from the racemates from the conventional methods, such as, for example, salt formation with an optically active acid followed by crystallization.
  • the present invention is intended to include all isotopes of atoms occurring in the present compounds.
  • Isotopes include those atoms having the same atomic number but different mass numbers.
  • isotopes of hydrogen include deuterium and tritium.
  • Isotopes of carbon include 13 C and 14 C.
  • Isotopically-labeled compounds of the invention can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described herein, using an appropriate isotopically-labeled reagent in place of the non-labeled reagent otherwise employed. Prodrugs and solvates of the inventive compounds are also contemplated.
  • prodrug denotes a compound which, upon administration to a subject, undergoes chemical conversion by metabolic or chemical processes to yield a compound of the formula I, and/or a salt and/or solvate thereof.
  • Any compound that will be converted in vivo to provide the bioactive agent i.e., the compound for formula I
  • compounds containing a carboxy group can form physiologically hydrolyzable esters which serve as prodrugs by being hydrolyzed in the body to yield formula I compounds per se.
  • prodrugs are preferably administered orally since hydrolysis in many instances occurs principally under the influence of the digestive enzymes.
  • physiologically hydrolyzable esters of compounds of formula I include C 1-6 alkylbenzyl, 4-methoxybenzyl, indanyl, phthalyl, methoxymethyl, C 1-6 alkanoyloxy-C 1-6 alkyl, e.g., acetoxymethyl, pivaloyloxymethyl or propionyloxymethyl, C1-6alkoxycarbonyloxy-C1-6alkyl, e.g., methoxycarbonyl-oxymethyl or ethoxycarbonyloxymethyl, glycyloxymethyl, phenylglycyloxymethyl, (5-methyl-2- oxo-1,3-dioxolen-4-yl)-methyl and other well known physiologically hydrolyzable esters used, for example, in the penicillin and cephalosporin arts.
  • esters may be prepared by conventional techniques known in the art.
  • Various forms of prodrugs are well known in the art and are described in Rautio, J. et al., Nature Review Drug Discovery, 17, 559-587 (2016).
  • Compounds described in the application and their salts may exist in their tautomeric form, in which hydrogen atoms are transposed to other parts of the molecules and the chemical bonds between the atoms of the molecules are consequently rearranged. It should be understood that the all tautomeric forms, insofar as they may exist, are included within the invention. Additionally, inventive compounds may have trans- and cis-isomers.
  • the disclosure herein further relates to compounds described herein, the tautomers and stereoisomeric forms thereof, and the pharmaceutically acceptable addition salts, and the solvates thereof, for use as a medicament. Furthermore, the disclosure herein relates to the use of a compound described herein, a tautomer or a stereoisomeric form thereof, or a pharmaceutically acceptable addition salt, or a solvate thereof, or a pharmaceutical composition according to the invention, for the manufacture of a medicament.
  • compositions may contain other therapeutic agents as described above and may be formulated, for example, by employing conventional solid or liquid vehicles or diluents, as well as pharmaceutical additives of a type appropriate to the mode of desired administration (e.g., excipients, binders, preservatives, stabilizers, flavors, etc.) according to techniques such as those well known in the art of pharmaceutical formulation.
  • the present invention further includes compositions comprising one or more compounds described herein and a pharmaceutically acceptable carrier.
  • a "pharmaceutically acceptable carrier” refers to media generally accepted in the art for the delivery of biologically active agents to animals, in particular, mammals. Pharmaceutically acceptable carriers are formulated according to a number of factors well within the purview of those of ordinary skill in the art.
  • compositions include without limitation the type and nature of the active agent being formulated; the subject to which the agent- containing composition is to be administered; the intended route of administration of the composition; and, the therapeutic indication being targeted.
  • Pharmaceutically acceptable carriers include both aqueous and non-aqueous liquid media, as well as a variety of solid and semi-solid dosage forms. Such carriers can include a number of different ingredients and additives in addition to the active agent, such additional ingredients being included in the formulation for a variety of reasons, e.g., stabilization of the active agent, binders, etc., well known to those of ordinary skill in the art.
  • compositions described herein may be administered by any means suitable for the condition to be treated, which may depend on the need for site-specific treatment or quantity of drug to be delivered.
  • Topical administration is generally preferred for skin- related diseases, and systematic treatment preferred for cancerous or pre-cancerous conditions, although other modes of delivery are contemplated.
  • the compounds may be delivered orally, such as in the form of tablets, capsules, granules, powders, or liquid formulations including syrups; topically, such as in the form of solutions, suspensions, gels or ointments; sublingually; bucally; parenterally, such as by subcutaneous, intravenous, intramuscular or intrasternal injection or infusion techniques (e.g., as sterile injectable aq. or non-aq. solutions or suspensions); nasally such as by inhalation spray; topically, such as in the form of a cream or ointment; rectally such as in the form of suppositories; or liposomally.
  • topically such as in the form of solutions, suspensions, gels or ointments
  • sublingually e.g., as sterile injectable aq. or non-aq. solutions or suspensions
  • nasally such as by inhalation spray
  • topically such as in the form of a cream or ointment
  • Dosage unit formulations containing non-toxic, pharmaceutically acceptable vehicles or diluents may be administered.
  • the compounds may be administered in a form suitable for immediate release or extended release. Immediate release or extended release may be achieved with suitable pharmaceutical compositions or, particularly in the case of extended release, with devices such as subcutaneous implants or osmotic pumps.
  • compositions for oral administration include suspensions which may contain, for example, microcrystalline cellulose for imparting bulk, alginic acid or sodium alginate as a suspending agent, methylcellulose as a viscosity enhancer, and sweeteners or flavoring agents such as those known in the art; and immediate release tablets which may contain, for example, microcrystalline cellulose, dicalcium phosphate, starch, magnesium stearate and/or lactose and/or other excipients, binders, extenders, disintegrants, diluents and lubricants such as those known in the art.
  • the inventive compounds may also be orally delivered by sublingual and/or buccal administration, e.g., with molded, compressed, or freeze-dried tablets.
  • compositions may include fast-dissolving diluents such as mannitol, lactose, sucrose, and/or cyclodextrins.
  • fast-dissolving diluents such as mannitol, lactose, sucrose, and/or cyclodextrins.
  • high molecular weight excipients such as celluloses (AVICEL®) or polyethylene glycols (PEG); an excipient to aid mucosal adhesion such as hydroxypropyl cellulose (HPC), hydroxypropyl methyl cellulose (HPMC), sodium carboxymethyl cellulose (SCMC), and/or maleic anhydride copolymer (e.g., GANTREZ®); and agents to control release such as polyacrylic copolymer (e.g., CARBOPOL 934®).
  • HPC hydroxypropyl cellulose
  • HPMC hydroxypropyl methyl cellulose
  • SCMC sodium carboxymethyl cellulose
  • Formulations for parenteral administration may be in the form of aqueous or non- aqueous isotonic sterile injection solutions or suspensions. These solutions and suspensions may be prepared from sterile powders or granules using one or more of the carriers or diluents mentioned for use in the formulations for oral administration or by using other suitable dispersing or wetting agents and suspending agents.
  • the compounds may be dissolved in water, polyethylene glycol, propylene glycol, ethanol, corn oil, cottonseed oil, peanut oil, sesame oil, benzyl alcohol, sodium chloride, tragacanth gum, and/or various buffers.
  • the active ingredient may also be administered by injection as a composition with suitable carriers including saline, dextrose, or water, or with cyclodextrin (i.e. Captisol), cosolvent solubilization (i.e. propylene glycol) or micellar solubilization (i.e. Tween 80).
  • suitable carriers including saline, dextrose, or water, or with cyclodextrin (i.e. Captisol), cosolvent solubilization (i.e. propylene glycol) or micellar solubilization (i.e. Tween 80).
  • compositions for parenteral administration include injectable solutions or suspensions which may contain, for example, suitable non-toxic, parenterally acceptable diluents or solvents, such as mannitol, 1,3-butanediol, water, Ringer's solution, an isotonic sodium chloride solution, or other suitable dispersing or wetting and suspending agents, including synthetic mono- or diglycerides, and fatty acids, including oleic acid.
  • suitable non-toxic, parenterally acceptable diluents or solvents such as mannitol, 1,3-butanediol, water, Ringer's solution, an isotonic sodium chloride solution, or other suitable dispersing or wetting and suspending agents, including synthetic mono- or diglycerides, and fatty acids, including oleic acid.
  • the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example as a solution in 1,
  • a sterile injectable oil-in-water microemulsion can, for example, be prepared by 1) dissolving at least one compound described herein in an oily phase, such as, for example, a mixture of soybean oil and lecithin; 2) combining the compound-containing oil phase with a water and glycerol mixture; and 3) processing the combination to form a microemulsion.
  • a sterile aqueous or oleaginous suspension can be prepared in accordance with methods already known in the art.
  • a sterile aqueous solution or suspension can be prepared with a non-toxic parenterally-acceptable diluent or solvent, such as, for example, 1,3-butane diol; and a sterile oleaginous suspension can be prepared with a sterile non-toxic acceptable solvent or suspending medium, such as, for example, sterile fixed oils, e.g., synthetic mono- or diglycerides; and fatty acids, such as, for example, oleic acid.
  • compositions for nasal aerosol or inhalation administration include solutions which may contain, for example, benzyl alcohol or other suitable preservatives, absorption promoters to enhance absorption and/or bioavailability, and/or other solubilizing or dispersing agents such as those known in the art.
  • Dispersible powders and granules can, for example, be prepared by admixing at least one compound described herein or a pharmaceutically acceptable salt thereof, with at least one dispersing and/or wetting agent; at least one suspending agent; and/or at least one preservative.
  • Exemplary preservatives include, but are not limited to, for example, anti-oxidants, e.g., ascorbic acid.
  • dispersible powders and granules can also contain at least one excipient, including, but not limited to, for example, sweetening agents; flavoring agents; and coloring agents.
  • excipients including, but not limited to, for example, sweetening agents; flavoring agents; and coloring agents.
  • exemplary compositions for rectal administration include suppositories which may contain, for example, suitable non-irritating excipients, such as cocoa butter, synthetic glyceride esters or polyethylene glycols, which are solid at ordinary temperatures but liquefy and/or dissolve in the rectal cavity to release the drug.
  • the therapeutically-effective amount of a compound of the present invention may be determined by one of ordinary skill in the art, and includes exemplary dosage amounts for a mammal of from about 0.05 to 1000 mg/kg; 1-1000 mg/kg; 1-50 mg/kg; 5-250 mg/kg; 250-1000 mg/kg of body weight of active compound per day, which may be administered in a single dose or in the form of individual divided doses, such as from 1 to 4 times per day.
  • the specific dose level and frequency of dosage for any particular subject may be varied and will depend upon a variety of factors, including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the species, age, body weight, general health, sex and diet of the subject, the mode and time of administration, rate of excretion, drug combination, and severity of the particular condition.
  • Preferred subjects for treatment include animals, most preferably mammalian species such as humans, and domestic animals such as dogs, cats, horses, and the like.
  • this term is intended to include all subjects, most preferably mammalian species that are affected by modulation of USP1-mediated functions.
  • the compounds described herein are useful for the treatment of cancer.
  • the present application provides a combined preparation of a compound described herein and/or a pharmaceutically acceptable salt thereof, a stereoisomer thereof or a tautomer thereof, and additional therapeutic agent(s) for simultaneous, separate or sequential use in the treatment and/or prophylaxis of multiple diseases or disorders associated with USP1.
  • the application provides a method of treating a patient suffering from or susceptible to a medical condition that is associated with USP1. A number of medical conditions can be treated. The method comprises administering to the patient a therapeutically effective amount of a composition comprising a compound described herien and/or a pharmaceutically acceptable salt thereof, a stereoisomer thereof or a tautomer thereof.
  • the compounds described herein may be used to treat or proliferative diseases such as cancer, immunological disorders or inflammatory disorders.
  • the compounds described herein may be used to treat cancers that are mediated by, dependent on or associated with USP1 activity.
  • the disease is a solid tumor.
  • the solid tumor is selected from prostate cancer, pancreatic cancer, bladder cancer, colorectal cancer, breast cancer, renal cancer, hepatocellular cancer, lung cancer, ovarian cancer, cervical cancer, gastric cancer, esophageal cancer, head and neck cancer, melanoma, neuroendocrine cancers, CNS cancers, brain tumors (e.g., glioma, anaplastic oligodendroglioma, adult glioblastoma multiforme, and adult anaplastic astrocytoma), bone cancer, or soft tissue sarcoma.
  • the solid tumor is from non-small cell lung cancer or small-cell lung cancer.
  • the compounds herein can be useful in the treatment of haematological malignancies.
  • hematological malignancy is selected from multiple myeloma, non-Hodgkin's lymphoma, Hodgkin lymphoma, T-cell leukaemia, mucosa-associated lymphoid tissue lymphoma, diffuse large B-cell lymphoma and mantle cell lymphoma.
  • solid tumor is selected from pancreatic cancer, breast cancer, melanoma and non-small cell lung cancer.
  • the cancer is selected from pituitary cancer, a hematopoietic tumor of lymphoid lineage, for example leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, B-cell lymphoma (e.g.
  • B-cell lymphoma diffuse large B-cell lymphoma, mantle cell lymphoma), T-cell leukaemia/lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, hairy cell lymphoma, or Burkett's lymphoma; a hematopoietic tumor of myeloid lineage, for example leukemias, acute and chronic myelogenous leukemias, chronic myelomonocytic leukemia (CMML), myeloproliferative disorder, myeloproliferative syndrome, myelodysplastic syndrome, or promyelocytic leukemia; multiple myeloma; thyroid follicular cancer; hepatocellular cancer, a tumor of mesenchymal origin (e.g.
  • Ewing's sarcoma for example fibrosarcoma or rhabdomyosarcoma; a tumor of the central or peripheral nervous system, for example astrocytoma, neuroblastoma, glioma (such as glioblastoma multiforme) or schwannoma; melanoma; seminoma; teratocarcinoma; osteosarcoma; xeroderma pigmentosum; keratoctanthoma; thyroid follicular cancer; or Kaposi's sarcoma.
  • the compounds described herein may be used to treat cancers that are mediated by, dependent on or associated with USP1 activity.
  • the disease is a solid tumor.
  • the solid tumor is from prostate cancer, pancreatic cancer, bladder cancer, colorectal cancer, breast cancer, renal cancer, hepatocellular cancer, lung cancer, ovarian cancer, cervical cancer, gastric cancer, esophageal cancer, head and neck cancer, melanoma, neuroendocrine cancers, CNS cancers, brain tumors (e.g., glioma, anaplastic oligodendroglioma, adult glioblastoma multiforme, and adult anaplastic astrocytoma), bone cancer, or soft tissue sarcoma.
  • the solid tumor is from non-small cell lung cancer or small-cell lung cancer.
  • the disease is a hematologic malignancy.
  • the disease is lymphoma, multiple myeloma, or leukemia.
  • the hematologic malignancy is leukemia or lymphoma.
  • the disease is acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), myelodysplastic syndrome (MDS), myeloproliferative disease (MPD), chronic myeloid leukemia (CML), juvenile myelomonocytic leukemia (JMML), multiple myeloma (MM), Hodgkin lymphoma, indolent non-Hodgkin's lymphoma (iNHL), refractory iNHL, non- Hodgkin's lymphoma (NHL), mantle cell lymphoma (MCL), follicular lymphoma, Waldenström’s macroglobulinemia
  • the disease is T-cell acute lymphoblastic leukemia (T-ALL), or B-cell acute lymphoblastic leukemia (B-ALL).
  • non-Hodgkin lymphoma can be indolent B-cell diseases including follicular lymphoma, lymphoplasmacytic lymphoma, Waldenström macroglobulinemia, and marginal zone lymphoma, as well as the aggressive lymphomas that include, for example, Burkitt lymphoma, diffuse large B- cell lymphoma (DLBCL) and mantle cell lymphoma (MCL).
  • the cancer is selected from hematological cancer, a lymphatic cancer.
  • the cancer comprises cancer cells with DNA damage repair pathway deficiency. In some embodiments, the cancer is a homologous recombination deficient cancer. In some embodiments, the cancer comprises cancer cells with a mutation in a gene encoding p53. In some embodiments, the mutation in a gene encoding p53 is a germline or somatic mutation. In some embodiments, the cancer comprises with cancer cells with loss of function mutation in a gene encoding p53. In some embodiments, the cancer is a BRCA1 and/or BRCA2 deficient cancer. In some embodiments, the cancer is a somatic or germline BRCA1 and/or BRCA2 mutant cancer.
  • the cancer is a Poly (ADP-ribose) polymerase (“PARP”) inhibitor refractory or resistant cancer.
  • PARP Poly (ADP-ribose) polymerase
  • the cancer is a PARP inhibitor resistant or refractory BRCA1 and/or BRCA2 deficient cancer.
  • the cancer cell has a germline or somatic mutation in a gene encoding ataxia telangiectasia mutated (ATM) protein kinase or ATM deficiency.
  • ATM telangiectasia mutated
  • the cancer has a mutation in the gene encoding more than two of p53, BRCA1, BRCA2, ATM.
  • the disease is an autoimmune or inflammatory disease or disorder.
  • autoimmune or inflammatory diseases or conditions may be chronic or acute and include, but are not limited to, inflammatory pelvic disease, urethritis, skin sunburn, sinusitis, pneumonitis, encephalitis, meningitis, myocarditis, pericarditis, nephritis including lupus nephritis, osteomyelitis, myositis, eczema, hepatitis, gastritis, enteritis, dermatitis, gingivitis, appendicitis, pancreatitis, primary biliary cirrhosis, cholecystitis, sclerosing cholangitis, agammaglobulinemia, psoriasis, allergy, Crohn's disease, irritable bowel syndrome, ulcerative colitis, Sjogren's disease, tissue graft rejection such as acute graft-versus-host disease, hyperacute rejection of transplanted organs, asthma, chronic obstruct
  • the autoimmune and inflammatory diseases and conditions may also include systemic or tissue inflammation, inflammatory responses to hypoxia, cellular activation and proliferation, lipid metabolism, fibrosis, infections with bacteria, infections with viruses (e.g., herpes virus, human papilloma virus, adenovirus, poxvirus and other DNA viruses), fungi, parasites or their toxins, such as sepsis, sepsis syndrome, septic shock, endotoxaemia, systemic inflammatory response syndrome (SIRS), multi-organ dysfunction syndrome, toxic shock syndrome, acute lung injury, ARDS (adult respiratory distress syndrome), acute renal failure, fulminant hepatitis, burns, acute pancreatitis, post-surgical syndromes, sarcoidosis, Herxheimer reactions, encephalitis, myelitis, meningitis, malaria and SIRS associated with viral infections such as influenza, herpes zoster, herpes simplex and coronavirus.
  • viruses e.g., herpes virus
  • the compounds described herein may be administered in conjunction with standard of care, e.g., surgery, radiation, and/or chemotherapy.
  • the compounds may be administered in conjunction with a chemotherapeutic agent.
  • the compounds may be administered in conjunction with one or more of carboplatin, cisplatin, paclitaxel, nab-paclitaxel, gemcitabine or FOLFOX.
  • the compounds may be administered in conjunction with carboplatin or nab-paclitaxel.
  • the compounds may be administered in conjunction with carboplatin and paclitaxel.
  • the compounds may be administered in conjunction with cisplatin and pemetrexed.
  • the compounds may be administered in conjunction with cisplatin and gemcitabine. In some embodiments, the compounds may be administered in conjunction with FOLFOX. In some embodiments, the compounds may be administered in conjunction with FOLFIRI. In one embodiment, the compounds may be administered in combination with decarbazine for the treatment of melanoma. In some embodiments, cisplatin is intravenously administered as a 100 mg/ml dose once every four weeks. In some embodiments, the compounds may be administered in conjunction with doxorubicin (adriamycin), cisplatin bleomycin sulfate, carmustine, chlorambucil, dacarbazine and/or cyclophosphamide hydroxyurea.
  • doxorubicin as adriamycin
  • cisplatin bleomycin sulfate carmustine
  • adriamycin is intravenously administered as a 60 mg/ml to 75 mg/ml dose once every 21 days.
  • the compounds of the present application e.g., a compound described herein or a pharmaceutically acceptable salt, prodrug, or solvate thereof
  • the one or more additional therapeutic agent may be an inhibitor to Janus kinase (JAK) such as JAK1, JAK2 and/or JAK3, Tyroansine kinase (TYK), K-Ras, Mitogen activated protein kinases (MAPK), Bruton's tyrosine kinase (BTK), bromodomain containing protein inhibitor (BRD) such as BRD4, a lysyl oxidase protein (LOX), lysyl oxidase-like protein (LOXL) such as LOXL1-5, matrix metalloprotease (MMP) such as MMP 1-10, adenosine A2B receptor (A2B), isocitrate dehydrogenase (IDH) such as IDH1, apoptosis signal-regulating kinase (ASK) such as ASK1, serine/threonine kinase TPL2, discoidin domain receptor (DDR) such as DDR1
  • the compounds of the present application may be used in combination with additional chemotherapeutic agent, an immunotherapeutic agent, a radiotherapeutic agent, an anti-neoplastic agent, an anti-cancer agent, an anti- fibrotic agent, an anti-angiogenic agent, a therapeutic antibody, or any combination thereof.
  • Chemotherapeutic agents may be categorized by their mechanism of action into, for example, the following groups: anti-metabolites/anti-cancer agents, such as pyrimidine analogs (floxuridine, capecitabine, and cytarabine); purine analogs, folate antagonists and related inhibitors antiproliferative/antimitotic agents including natural products such as vinca alkaloid (vinblastine, vincristine) and microtubule such as taxane (paclitaxel, docetaxel), vinblastin, nocodazole, epothilones and navelbine, epidipodophyllotoxins (etoposide, teniposide); DNA damaging agents (actinomycin, amsacrine, busulfan, carboplatin, chlorambucil, cisplatin, cyclophosphamide, Cytoxan, dactinomycin, daunorubicin, doxorubicin, epirubicin, iphosphamide,
  • chemotherapeutic agents include alkylating agents such as thiotepa and cyclophosphamide; alkyl sulfonates such as busulfan, improsulfan and piposulfan; aziridines such as benzodopa, carboquone, meturedopa, and uredopa; emylerumines and memylamelamines including alfretamine, triemylenemelamine, triethylenephosphoramide, triethylenethiophosphoramide and trimemylolomelamine; acetogenins (especially bullatacin and bullatacinone); a camptothecin (including synthetic analogue topotecan); bryostatin; callystatin; CC-1065 (including its adozelesin, carzelesin and bizelesin synthetic analogues); cryptophycins (articularly cryptophycin 1 and cryptophycin 8); dolastatin; duocarmycin (including the synthetic al
  • Chemotherapeutic agents may also include, for example, anti-hormonal agents that act to regulate or inhibit hormone action on tumors such as anti-estrogens and selective estrogen receptor modulators (SERMs), including, for example, tamoxifen, raloxifene, droloxifene, 4-hydroxytamoxifen, trioxifene, keoxifene, onapristone, and toremifene; inhibitors of the enzyme aromatase, which regulates estrogen production in the adrenal glands, such as, for example, 4(5)-imidazoles, aminoglutethimide, megestrol acetate, exemestane, formestane, fadrozole, vorozole letrozole and anastrozole; and anti- androgens such as flutamide, nilutamide, bicalutamide, leuprohde, and goserelin; and pharmaceutically acceptable salts
  • SERMs selective estrogen receptor modulators
  • the anti-angiogenic agents include, but are not limited to, retinoid acid and derivatives thereof, 2-methoxyestradiol, suramin, squalamine, tissue inhibitor of metalloproteinase-1, tissue inhibitor of metalloproternase-2, plasminogen activator inhibitor-1, plasminogen activator inbibitor-2, cartilage-derived inhibitor, paclitaxel (nab- paclitaxel), platelet factor 4, protamine sulphate (clupeine), sulphated chitin derivatives (prepared from queen crab shells), sulphated polysaccharide peptidoglycan complex (sp- pg), staurosporine, modulators of matrix metabolism, including for example, proline analogs ((1-azetidine-2-carboxylic acid (LACA), cishydroxyproline, d,I-3,4- dehydroproline, thiaproline, .alpha.-dipyridyl, beta-aminopropion
  • anti-angiogenesis agents include antibodies, preferably monoclonal antibodies against these angiogenic growth factors: beta-FGF, alpha-FGF, FGF-5, VEGF isoforms, VEGF- C, HGF/SF and Ang-1/Ang-2.
  • the application also provides a method for treating a subject who is undergoing one or more standard therapies, such as chemotherapy, radiotherapy, immunotherapy, surgery, or combination thereof. Accordingly, one or more therapeutic agent or inhibitors may be administered before, during, or after administration of chemotherapy, radiotherapy, immunotherapy, surgery or combination thereof.
  • the subject may be a human who is (i) substantially refractory to at least one chemotherapy treatment, or (ii) in relapse after treatment with chemotherapy, or both (i) and (ii). In some of embodiments, the subject is refractory to at least two, at least three, or at least four chemotherapy treatments (including standard or experimental chemotherapies).
  • the subject is refractory to at least one, at least two, at least three, or at least four chemotherapy treatment (including standard or experimental chemotherapy) selected from fludarabine, rituximab, obinutuzumab, alkylating agents, alemtuzumab and other chemotherapy treatments such as CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone); R-CHOP (rituximab-CHOP); hyperCVAD (hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, cytarabine); R-hyperCVAD (rituximab-hyperCVAD); FCM (fludarabine, cyclophosphamide, mitoxantrone); R-FCM (rituximab, fludarabine, cyclophosphamide, mitoxantrone); bortezom
  • chemotherapy treatment
  • immunotherapeutic agents treating lymphoma or leukemia include, but are not limited to, rituximab (such as Rituxan), alemtuzumab (such as Campath, MabCampath), anti-CD19 antibodies, anti-CD20 antibodies, anti-MN-14 antibodies, anti- TRAIL, Anti-TRAIL DR4 and DR5 antibodies, anti-CD74 antibodies, apolizumab, bevacizumab, CHIR-12.12, epratuzumab (hLL2-anti-CD22 humanized antibody), galiximab, ha20, ibritumomab tiuxetan, lumiliximab, milatuzumab, ofatumumab, PRO131921, SGN-40, WT-1 analog peptide vaccine, WT1126-134
  • Additional immunotherapy agents includes using cancer vaccines based upon the genetic makeup of an individual patient's tumor, such as lymphoma vaccine GTOP-99.
  • the therapeutic treatments can be supplemented or combined with any of the abovementioned therapies with stem cell transplantation or treatment.
  • One example of modified approach is radioimmunotherapy, wherein a monoclonal antibody is combined with a radioisotope particle, such as indium In-111, yttrium Y-90, iodine I-131.
  • combination therapies include, but are not limited to, Iodine-131 tositumomab, Yttrium-90 ibritumomab tiuxetan with CHOP.
  • the compounds of the application can be used in combination with additional therapeutic procedures.
  • Other therapeutic procedures include peripheral blood stem cell transplantation, autologous hematopoietic stem cell transplantation, autologous bone marrow transplantation, antibody therapy, biological therapy, enzyme inhibitor therapy, total body irradiation, infusion of stem cells, bone marrow ablation with stem cell support, in vitro-treated peripheral blood stem cell transplantation, umbilical cord blood transplantation, immunoenzyme technique, pharmacological study, low-LET cobalt-60 gamma ray therapy, bleomycin, conventional surgery, radiation therapy, and nonmyeloablative allogeneic hematopoietic stem cell transplantation.
  • the compounds of the application can be used in combination with anti-fibrotic agents.
  • the anti-fibrotic agents include, but are not limited to, emylenemamine, hydrazine, phenylhydrazine, and their derivatives, semicarbazide, and urea derivatives, aminonitriles, such as beta-aminopropionitrile (BAPN), or 2-nitroethylamine, unsaturated or saturated haloamines, such as 2-bromo-ethylamine, 2-chloroethylamine, 2- trifluoroethylamine, 3-bromopropylamine, p-halobenzylamines, selenohomocysteine lactone.
  • the anti-fibrotic agents are copper chelating agents, penetrating or not penetrating the cells.
  • Exemplary compounds include indirect inhibitors such compounds blocking the aldehyde derivatives originating from the oxidative deamination of the lysyl and hydroxylysyl residues by the lysyl oxidases, such as the thiolamines, in particular D- penicillamine, or its analogues such as 2-amino-5-mercapto-5-methylhexanoic acid, D-2- amino-3-methyl-3-((2-acetamidoethyl)dithio)butanoic acid, p-2-amino-3-methyl-3-((2- aminoethyl)dithio)butanoic acid, sodium-4-((p-1-dimethyl-2-amino-2- carboxyethyl)dithio)butane sulphurate, 2-acetamidoethyl-2-acetamidoethanethiol sulphanate, sodium-4-mercaptobutanesulphinate trihydrate.
  • indirect inhibitors such
  • the compounds of the application can be used in combination with immunotherapeutic and anti-inflammatory treatments.
  • the immunotherapeutic agents include and are not limited to therapeutic antibodies suitable for treating patients; such as abagovomab, adecatumumab, afutuzumab, alemtuzumab, altumomab, amatuximab, anatumomab, arcitumomab, bavituximab, bectumomab, bevacizumab, bivatuzumab, blinatumomab, brentuximab, cantuzumab, catumaxomab, cetuximab, citatuzumab, cixutumumab, clivatuzumab, conatumumab, daratumumab, drozitumab, duligotumab, dusigitumab, detumomab, dacetuzumab, da
  • the exemplified therapeutic antibodies may be further labeled or combined with a radioisotope particle, such as indium In-111, yttrium Y-90, iodine I-131.
  • the immuno-oncology agent is (i) an agonist of a stimulatory (including a co-stimulatory) receptor or (ii) an antagonist of an inhibitory (including a co- inhibitory) signal on T cells, both of which result in amplifying antigen-specific T cell responses (often referred to as immune checkpoint regulators).
  • Certain of the stimulatory and inhibitory molecules are members of the immunoglobulin super family (IgSF).
  • B7 family which includes B7- 1, B7-2, B7-H1 (PD-L1), B7-DC (PD-L2), B7-H2 (ICOS-L), B7-H3, B7-H4, B7-H5 (VISTA), and B7-H6.
  • TNF family of molecules that bind to cognate TNF receptor family members which includes CD40 and CD40L, OX-40, OX-40L, CD70, CD27L, CD30, CD30L, 4-1BBL, CD137 (4-1BB), TRAIL/Apo2-L, TRAILR1/DR4, TRAILR2/DR5, TRAILR3, TRAILR4, OPG, RANK, RANKL, TWEAKR/Fn14, TWEAK, BAFFR, EDAR, XEDAR, TACI, APRIL, BCMA, LT ⁇ R, LIGHT, DcR3, HVEM, VEGI/TL1A, TRAMP/DR3, EDAR, EDA1, XEDAR, EDA2, TNFR1, Lymphotoxin ⁇ /TNF ⁇ , TNFR2, TNF ⁇ , LT ⁇ R, Lymphotoxin ⁇ 1 ⁇ 2, FAS
  • T cell responses can be stimulated by a combination of a compound of Formula (I) and one or more of (i) an antagonist of a protein that inhibits T cell activation (e.g., immune checkpoint inhibitors) such as CTLA-4, PD-1, PD-L1, PD-L2, LAG-3, TIM-3, Galectin 9, CEACAM-1, BTLA, CD69, Galectin-1, TIGIT, CD113, GPR56, VISTA, 2B4, CD48, GARP, PD1H, LAIR1, TIM-1, and TIM-4, and (ii) an agonist of a protein that stimulates T cell activation such as B7-1, B7-2, CD28, 4-1BB (CD137), 4-1BBL, ICOS, ICOS-L, OX40, OX40L, GITR, GITRL, CD70, CD27, CD40, DR3 and CD28H.
  • an antagonist of a protein that inhibits T cell activation e.g., immune check
  • agents that can be combined with compounds described herein for the treatment of cancer include antagonists of inhibitory receptors on NK cells or agonists of activating receptors on NK cells.
  • compounds described herien can be combined with antagonists of KIR, such as lirilumab.
  • agents for combination therapies include agents that inhibit or deplete macrophages or monocytes, including but not limited to CSF-1R antagonists such as CSF-1R antagonist antibodies including RG7155 (WO11/70024, WO11/107553, WO11/131407, WO13/87699, WO13/119716, WO13/132044) or FPA-008 (WO11/140249; WO13169264; WO14/036357).
  • compounds of the present application can be used with one or more of agonistic agents that ligate positive costimulatory receptors, blocking agents that attenuate signaling through inhibitory receptors, antagonists, and one or more agents that increase systemically the frequency of anti-tumor T cells, agents that overcome distinct immune suppressive pathways within the tumor microenvironment (e.g., block inhibitory receptor engagement (e.g., PD-L1/PD-1 interactions), deplete or inhibit Tregs (e.g., using an anti-CD25 monoclonal antibody (e.g., daclizumab) or by ex vivo anti-CD25 bead depletion), inhibit metabolic enzymes such as IDO, or reverse/prevent T cell anergy or exhaustion) and agents that trigger innate immune activation and/or inflammation at tumor sites.
  • agonistic agents that ligate positive costimulatory receptors e.g., blocking agents that attenuate signaling through inhibitory receptors, antagonists, and one or more agents that increase systemically the frequency
  • the immuno-oncology agent is a CTLA-4 antagonist, such as an antagonistic CTLA-4 antibody.
  • Suitable CTLA-4 antibodies include, for example, YERVOY (ipilimumab) or tremelimumab.
  • the immuno-oncology agent is a PD-1 antagonist, such as an antagonistic PD-1 antibody.
  • Suitable PD-1 antibodies include, for example, OPDIVO (nivolumab), KEYTRUDA (pembrolizumab), or MEDI-0680 (AMP-514; WO2012/145493).
  • the immuno-oncology agent may also include pidilizumab (CT-011), though its specificity for PD-1 binding has been questioned.
  • the immuno-oncology agent is a PD-L1 antagonist, such as an antagonistic PD-L1 antibody.
  • Suitable PD-L1 antibodies include, for example, MPDL3280A (RG7446; WO2010/077634), durvalumab (MEDI4736), BMS-936559 (WO2007/005874), and MSB0010718C (WO2013/79174).
  • the immuno-oncology agent is a LAG-3 antagonist, such as an antagonistic LAG-3 antibody.
  • Suitable LAG3 antibodies include, for example, BMS- 986016 (WO10/19570, WO14/08218), or IMP-731 or IMP-321 (WO08/132601, WO09/44273).
  • the immuno-oncology agent is a CD137 (4-1BB) agonist, such as an agonistic CD137 antibody.
  • Suitable CD137 antibodies include, for example, urelumab and PF-05082566 (WO12/32433).
  • the immuno-oncology agent is a GITR agonist, such as an agonistic GITR antibody.
  • Suitable GITR antibodies include, for example, BMS-986153, BMS-986156, TRX-518 (WO06/105021, WO09/009116) and MK-4166 (WO11/028683).
  • the immuno-oncology agent is an IDO antagonist.
  • IDO antagonists include, for example, INCB-024360 (WO2006/122150, WO07/75598, WO08/36653, WO08/36642), indoximod, BMS-986205, or NLG-919 (WO09/73620, WO09/1156652, WO11/56652, WO12/142237).
  • the immuno-oncology agent is an OX40 agonist, such as an agonistic OX40 antibody.
  • Suitable OX40 antibodies include, for example, MEDI-6383 or MEDI-6469.
  • the immuno-oncology agent is an OX40L antagonist, such as an antagonistic OX40 antibody.
  • Suitable OX40L antagonists include, for example, RG-7888 (WO06/029879).
  • the immuno-oncology agent is a CD40 agonist, such as an agonistic CD40 antibody.
  • the immuno-oncology agent is a CD40 antagonist, such as an antagonistic CD40 antibody.
  • Suitable CD40 antibodies include, for example, lucatumumab or dacetuzumab.
  • the immuno-oncology agent is a CD47 antagonist, such as a CD47 antagonist selected from the group MIAP301, MIAP410, TTI-621, CV1, Hu5F9- G4, CC-90002, B6H12 and 2D3.
  • the immuno-oncology agent is a CD27 agonist, such as an agonistic CD27 antibody. Suitable CD27 antibodies include, for example, varlilumab.
  • the immuno-oncology agent is MGA271 (to B7H3) (WO11/109400).
  • the combination therapy is intended to embrace administration of these therapeutic agents in a sequential manner, that is, wherein each therapeutic agent is administered at a different time, as well as administration of these therapeutic agents, or at least two of the therapeutic agents, in a substantially simultaneous manner.
  • Substantially simultaneous administration can be accomplished, for example, by administering to the subject a single dosage form having a fixed ratio of each therapeutic agent or in multiple, single dosage forms for each of the therapeutic agents.
  • Sequential or substantially simultaneous administration of each therapeutic agent can be effected by any appropriate route including, but not limited to, oral routes, intravenous routes, intramuscular routes, and direct absorption through mucous membrane tissues.
  • the therapeutic agents can be administered by the same route or by different routes.
  • a first therapeutic agent of the combination selected may be administered by intravenous injection while the other therapeutic agents of the combination may be administered orally.
  • all therapeutic agents may be administered orally or all therapeutic agents may be administered by intravenous injection.
  • Combination therapy also can embrace the administration of the therapeutic agents as described above in further combination with other biologically active ingredients and non-drug therapies (e.g., surgery or radiation treatment.) Where thwe combination therapy further comprises a non drug treatment, the non drug treatment may be conducted at any suitable time so long as a beneficial effect from the co-action of the combination of the therapeutic agents and non-drug treatment is achieved.
  • the beneficial effect is still achieved when the non drug treatment is temporally removed from the administration of the therapeutic agents, perhaps by days or even weeks.
  • the present invention also provides the compounds of the present invention for use in therapy.
  • compounds of Formula I are selected from exemplified compounds or combinations of exemplified compounds or other embodiments herein.
  • the present invention may be embodied in other specific forms without departing from the spirit or essential attributes thereof. This invention encompasses all combinations of preferred aspects and/or embodiments of the invention noted herein.
  • any and all embodiments of the present invention may be taken in conjunction with any other embodiment or embodiments to describe additional more preferred embodiments. It is also to be understood that each individual element of the preferred embodiments is its own independent preferred embodiment. Furthermore, any element of an embodiment is meant to be combined with any and all other elements from any embodiment to describe an additional embodiment.
  • METHODS OF PREPARATION The compounds of the present invention can be prepared in a number of ways well known to one skilled in the art of organic synthesis.
  • the compounds of the present invention can be synthesized using the methods described below, together with synthetic methods known in the art of synthetic organic chemistry, or variations thereon as appreciated by those skilled in the art. Preferred methods include, but are not limited to, those described below.
  • the compounds of this invention may be prepared using the reactions and techniques described in this section. The reactions are performed in solvents appropriate to the reagents and materials employed and are suitable for the transformations being effected. Also, in the description of the synthetic methods described below, it is to be understood that all proposed reaction conditions, including choice of solvent, reaction atmosphere, reaction temperature, duration of the experiment and work up procedures, are chosen to be the conditions standard for that reaction, which should be readily recognized by one skilled in the art. It is understood by one skilled in the art of organic synthesis that the functionality present on various portions of the molecule must be compatible with the reagents and reactions proposed.
  • Method B Column: Waters Acquity BEH C18 1.7 um 2.1 x 50 mm; Mobile phase A: 0.05% TFA in ACN:Water (5:95); Mobile phase B: 0.05% TFA in ACN:Water (95:5); Flow rate: 1 ml/min.; Temperature: 50° C; Gradient: 0% B to 100% B over 1 min, stop time 1.5 min; MS and UV: 220, 254.
  • Method C Column: XBridge C18, 2.1 mm x 50 mm, 1.7 ⁇ m particles; Mobile phase A: 0.05% TFA in ACN:Water (5:95); Mobile phase B: 0.05% TFA in ACN:Water (95:5); Flow rate: 1 ml/min.; Temperature: 50° C; Gradient: 0-100 % B (0-3 min), 100 % B (3-3.5 min); MS and UV: 220.
  • Method D Column: Acquity BEH C18(50X3.0) mm, 1.7 ⁇ m;Mobile phase A: 5 mm ammonium formate pH 3.3 : ACN (98:2); Mobile phase B: ACN : 5 mm ammonium formate pH 3.3 (98:2); Flow rate: 0.7 ml/min; Temperature: 25° C; Gradient: 20% B to 98% B over 1.5 min, 0.5 min hold at 98% B; MS and UV: 220 nm.
  • Method E Column: Kinetex XB-C18(75X3.0) mm, 2.6 ⁇ m; Mobile phase A: 5 mm ammonium formate pH 3.3 : ACN (98:2); Mobile phase B: ACN : 5mm ammonium formate pH 3.3 (98:2); Flow rate: 1 ml/min; Temperature: 25° C; Gradient: 20% B to 100% B over 4 min, 1.5 ml/min flow at 0.5 min hold at 100% B; MS and UV: 220 & 254.
  • Method F Column: Acquity UPLC BEH C18(50X3.0) mm, 1.7 ⁇ m; Mobile phase A: 5 mm ammonium formate pH 3.3 : Acetonitrile (98:2); Mobile phase B: ACN :5 mm ammonium formate pH 3.3 (98:2); Flow rate: 0.7 ml/min; Temperature: 25° C; Gradient: 20% B to 98% B over 1.5 min, 0.5 min hold at 98% B; MS and UV: 220 nm.
  • Step 2 Synthesis of methyl 4-(1-methyl-4-(trifluoromethyl)-1H-imidazol-2- yl)benzoate 3
  • methyl 4-(4-(trifluoromethyl)-1H-imidazol-2-yl)benzoate 2 (2.50 g, 9.25 mmol) in DMF (20 mL) was added sodium hydride (60% dispersion in mineral oil, 0.740 g, 18.5 mmol) followed by iodomethane (0.87 mL, 13.9 mmol) at 0 o C.
  • the mixture was stirred at RT for 3 hrs, chilled water was added, and the contents extracted with ethyl acetate.
  • Step 3 Synthesis of (4-(1-methyl-4-(trifluoromethyl)-1H-imidazol-2- yl)phenyl)methanol 4a
  • methyl 4-(1-methyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzoate 3 (1.20 g, 4.22 mmol) in THF (25 mL) at 0 o C
  • lithium aluminium hydride (2 M in THF, 4.22 mL, 8.44 mmol
  • Step 1 Synthesis of 4-chloro-1-isopropyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole, Intermediate 11 Step 1: Synthesis of 4-chloro-1-isopropyl-1H-pyrazole 10 To a stirred solution of 4-chloro-1H-pyrazole 9 (5.0 g, 49 mmol) in acetonitrile (60 mL) was added Cs2CO3 (32 g, 98 mmol) followed by addition of 2-iodopropane (5.69 mL, 58.5 mmol). This mixture was heated at 80 °C for 2 hrs. After completion of the reaction, the reaction mixture was cooled to RT.
  • Step 2 Synthesis of 4-chloro-1-isopropyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2- yl)-1H-pyrazole 11
  • 4-chloro-1-isopropyl-1H-pyrazole 10 5.50 g, 38.0 mmol
  • tetrahydrofuran 50 mL
  • n-butyllithium 1.6 M in hexanes, 28.5 mL, 45.6 mmol
  • reaction mixture was cooled to -78 o C before the addition of 2-isopropoxy- 4,4,5,5-tetramethyl-1,3,2-dioxaborolane (8.49 g, 45.6 mmol). This was stirred for 2 hrs at -78 o C. The reaction was then warmed to RT and saturated aqueous NH4Cl was added, and the contents extracted with ethyl acetate.
  • Example 1 2-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-4-((4-(1-methyl-4- (trifluoromethyl)-1H-imidazol-2-yl)benzyl)oxy)furo[3,2-d]pyrimidine
  • Step 1 Synthesis of 2-chloro-4-((4-(1-methyl-4-(trifluoromethyl)-1H-imidazol-2- yl)benzyl)oxy)furo[3,2-d]pyrimidine 13
  • 4-(1-methyl-4-(trifluoromethyl)-1H-imidazol-2- yl)phenyl)methanol 4a, (79 mg, 0.31 mmol) and 2,4-dichlorofuro[3,2-d]pyrimidine 12, (58.3 mg, 0.308 mmol) in DMF (2.0 mL) was added cesium carbonate (201 mg, 0.617 mmol).
  • reaction mixture was purged with nitrogen and stirred for 2 min at RT. Then tetrakis(triphenylphosphine)palladium(0) (7.49 mg, 0.0065 mmol) was added and the contents degassed with nitrogen. The resulting mixture was heated to 100 °C for 2 hrs. The reaction was cooled to ambient temperature and filtered.
  • Example 2 was prepared using the same methods as described for Example 1.
  • Step 2 Synthesis of 2-chloro-4-((1-(4-(trifluoromethyl)pyridin-2-yl)piperidin-4- yl)methoxy)furo[3,2-d]pyrimidine 17
  • (1-(4-(trifluoromethyl)pyridin-2-yl)piperidin-4-yl)methanol 16 120 mg, 0.461 mmol
  • NaH 55.3 mg, 1.38 mmol
  • the reaction mixture was allowed stir at RT for 20 min followed by the addition of 2,4-dichlorofuro[3,2-d]pyrimidine 12 (87 mg, 0.46 mmol).
  • Step 3 Synthesis of 2-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-4-((1-(4- (trifluoromethyl)pyridin-2-yl)piperidin-4-yl)methoxy)furo[3,2-d]pyrimidine,
  • Example 3 To a stirred solution of 2-chloro-4-((1-(4-(trifluoromethyl)pyridin-2-yl)piperidin-4- yl)methoxy)furo[3,2-d]pyrimidine 17 (28 mg, 0.068 mmol) and 4-cyclopropyl-6-methoxy- 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine (28.1 mg, 0.102 mmol) in 1,4- dioxane (2 mL) and H2O (0.133 mL) was added sodium carbonate (14.4 mg, 0.136 mmol) in a 20 ml scintillation via
  • Example 4 was prepared using the same methods as described for Example 3.
  • Step 2 Synthesis of 2-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-4-((4-(1-methyl-4- (trifluoromethyl)-1H-imidazol-2-yl)benzyl)oxy)pyrrolo[2,1-f][1,2,4]triazine,
  • Example 1 To a stirred solution of 4-cyclopropyl-6-methoxy-5-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)pyrimidine (31 mg, 0.11 mmol) and 2-chloro-4-((4-(1-methyl-4- (trifluoromethyl)-1H-imidazol-2-yl)benzyl)oxy)pyrrolo[2,1-f][1,2,4]triazine 19 (30 mg, 0.074 mmol) in 1,4-dioxane (1 mL)) and H 2 O (0.067 mL) was added Cs 2 CO 3 (47.9
  • reaction mixture was purged with N 2 and stirred for 2 min at RT, tetrakis(triphenylphosphine)palladium(0) (8.50 mg, 7.36 ⁇ mol) was added and the contents degassed with N2 for 5 min. The resulting mixture was heated to 100 °C for 2 hrs, cooled to RT and concentrated.
  • Example 6 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-4-((4-(1-methyl-4- (trifluoromethyl)-1H-imidazol-2-yl)benzyl)oxy)-1H-pyrazolo[3,4-d]pyrimidine 5
  • Step 1 Synthesis of 4,6-dichloro-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4- 3,4-Dihydro-2H-pyran (0.653 mL, 7.14 mmol) was added to a mixture of 4,6-dichloro-1H- pyrazolo[3,4-d]pyrimidine 21 (500 mg, 2.65 mmol) and TsOH (20.1 mg, 0.106 mmol) in EtOAc (15 mL).
  • Steps 2 and 3 Synthesis of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-4-((4-(1- methyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)oxy)-1-(tetrahydro-2H-pyran-2- yl)-1H-pyrazolo[3,4-d]pyrimidine 23
  • 6-(4-Cyclopropyl-6-methoxypyrimidin-5-yl)-4-((4-(1-methyl-4-(trifluoromethyl)-1H- imidazol-2-yl)benzyl)oxy)-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-d]pyrimidine 23 was prepared according to procedure described in Example 5 starting from 4,6-dichloro- 1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-d]pyrimidine 21
  • Step 4 Synthesis of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-4-((4-(1-methyl-4- (trifluoromethyl)-1H-imidazol-2-yl)benzyl)oxy)-1H-pyrazolo[3,4-d]pyrimidine, A stirred solution of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-4-((4-(1-methyl-4- (trifluoromethyl)-1H-imidazol-2-yl)benzyl)oxy)-1-(tetrahydro-2H-pyran-2-yl)-1H- pyrazolo[3,4-d]pyrimidine 23 (38 mg, 0.063 mmol) in DCM (3 mL) was cooled to 0 °C.
  • Step 2 Synthesis of 2,3-dimethyl-2,7-dihydro-4H-pyrazolo[3,4-d]pyrimidine- 4,6(5H)-dione 26
  • Ethyl 3-amino-1,5-dimethyl-1H-pyrazole-4-carboxylate 25 (1 g, 5.46 mmol) was melted at 200 °C with urea (1.64 g, 27.3 mmol) for 3 hrs. The reaction was cooled to 40 °C, and 10 mL of water was added. The mixture was then boiled for 1 hr and stirred at RT for 16 hrs.
  • Step 3 Synthesis of 4,6-dichloro-2,3-dimethyl-2H-pyrazolo[3,4-d]pyrimidine 27
  • 2,3-dimethyl-2,7-dihydro-4H-pyrazolo[3,4-d]pyrimidine-4,6(5H)- dione 26 (220 mg, 1.22 mmol) in N,N-dimethylaniline (155 ⁇ l, 12.2 mmol) was added POCl 3 (341 ⁇ l, 3.66 mmol).
  • Steps 4 and 5 Synthesis of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-2,3-dimethyl- 4-((4-(1-methyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)oxy)-2H-pyrazolo[3,4- d]pyrimidine,
  • Example 7 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-2,3-dimethyl-4-((4-(1-methyl-4- (trifluoromethyl)-1H-imidazol-2-yl)benzyl)oxy)-2H-pyrazolo[3,4-d]pyrimidine,
  • Example 7 was prepared according to procedure described in Example 5 starting from 4,6-dichloro- 2,3-dimethyl-2H-pyrazolo[3,4-d]pyrimidine 25.
  • Step 1 Synthesis of 2-chloro-4-((4-(5-methyl-3-(trifluoromethyl)-1H-pyrazol-1- yl)benzyl)oxy)-6,7-dihydrothieno[3,2-d]pyrimidine 30
  • 2,4-dichloro-6,7-dihydrothieno[3,2-d]pyrimidine 29 75 mg, 0.36 mmol
  • (4-(5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)phenyl)methanol 8 (93 mg, 0.36 mmol) in anhydrous THF (1.0 mL) at 0 °C under nitrogen was added a solution of 1.0 M sodium bis(trimethylsilyl)amide solution in THF (362 ⁇ l, 0.362 mmol) and the reaction mixture was stirred at 0 °C for 1 hr and RT for 18 hrs.
  • the reaction mixture was diluted with EtOAc (5 mL), washed with a solution of aqueous 10% lithium chloride solution (3 x 15 mL), dried over sodium sulfate and concentrated.
  • the crude product was subjected to ISCO flash chromatography (silica gel/hexane-EtOAc 100:0 to 0:100 gradient) to yield 2- chloro-4-((4-(5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzyl)oxy)-6,7- dihydrothieno[3,2-d]pyrimidine 30 (40 mg, 0.094 mmol, 26% yield) as light brown gum.
  • Example 9 was prepared using the same methods as described for Example 8.
  • Step 4 Synthesis of 2-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-4-((4-(1-methyl-4- (trifluoromethyl)-1H-imidazol-2-yl)benzyl)oxy)-5H-pyrrolo[3,2-d]pyrimidine,
  • Example 10 A solution of 2-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-4-((4-(1-methyl-4- (trifluoromethyl)-1H-imidazol-2-yl)benzyl)oxy)-5-((2-(trimethylsilyl)ethoxy)methyl)-5H- pyrrolo[3,2-d]pyrimidine 35 (0.30 g, 0.46 mmol) in trifluoroacetic acid (532 ⁇ L, 6.90 mmol) was stirred at 0 o C for 2 hrs, during which the temperature of the solution was allowed to rise to ambient temperature.
  • USP1-UAF1 Rhodamine assay USP1/UAF1 ubiquitin-rhodamine 110 hydrolysis assays were performed at room temperature in black, low-volume 384 well plates (Corning 3821). 100X solutions of compounds in DMSO were prepared by three-fold serial dilutions starting from a 10 mM stock.
  • 2X solutions of His6-USP1/His6-UAF1 (200 pM, Internally Produced) and ubiquitin-rhodamine 110 (10 ⁇ M, South Bay Bio SBB-PS0001) were prepared in assay buffer (50 mM Tris pH 7.5, 100 mM NaCl, 1 mM EDTA, 1 mM TCEP, 100 ng/ ⁇ L BSA).
  • assay buffer 50 mM Tris pH 7.5, 100 mM NaCl, 1 mM EDTA, 1 mM TCEP, 100 ng/ ⁇ L BSA.
  • Serially diluted compounds in DMSO were transferred to the assay plate by acoustic dispensing (100 nL per well).5 ⁇ L of assay buffer was added to column 1 of the plates, and 5 ⁇ L of 2X USP1/UAF1 solution was added to columns 2-24 and incubated with compounds for 3 hrs.
  • Reactions were initiated by addition of 5 ⁇ L of 2X ubiquitin- rhodamine 110 solution to each well for final concentrations of 100 pM USP1/UAF1 and 5 ⁇ M ubiquitin-rhodamine 110. Fluorescence was read at the minimum kinetic interval for 1 h using a BioTek Synergy HTX plate reader (Agilent Technologies) with excitation at 485 nm and emission at 528 nm. Initial rates were calculated by fitting the linear range of the plot of fluorescence vs time to a linear equation. IC50 values were calculated from dose- response curves.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des composés de formule suivante (I) ou un stéréoisomère ou un sel pharmaceutiquement acceptable de ceux-ci, tous les substituants étant tels que définis dans la description, lesdits composés étant des inhibiteurs d'USP1 utiles pour le traitement de maladies comprenant, entre autres, des maladies prolifératives, métaboliques, allergiques, auto-immunes et inflammatoires.
PCT/US2024/053489 2023-10-31 2024-10-30 Composés de type protéase 1 spécifique de l'ubiquitine (usp1) Pending WO2025096487A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363594446P 2023-10-31 2023-10-31
US63/594,446 2023-10-31

Publications (1)

Publication Number Publication Date
WO2025096487A1 true WO2025096487A1 (fr) 2025-05-08

Family

ID=93520789

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/053489 Pending WO2025096487A1 (fr) 2023-10-31 2024-10-30 Composés de type protéase 1 spécifique de l'ubiquitine (usp1)

Country Status (1)

Country Link
WO (1) WO2025096487A1 (fr)

Citations (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006029879A2 (fr) 2004-09-17 2006-03-23 F.Hoffmann-La Roche Ag Anticorps anti-ox40l
WO2006105021A2 (fr) 2005-03-25 2006-10-05 Tolerrx, Inc. Molecules de liaison gitr et leurs utilisations
WO2006122150A1 (fr) 2005-05-10 2006-11-16 Incyte Corporation Modulateurs de l'indolamine 2,3-dioxygenase et leurs procedes d'utilisation
WO2007005874A2 (fr) 2005-07-01 2007-01-11 Medarex, Inc. Anticorps monoclonaux humains diriges contre un ligand de mort programmee de type 1(pd-l1)
WO2007075598A2 (fr) 2005-12-20 2007-07-05 Incyte Corporation N-hydroxyamidinoheterocycles en tant que modulateurs d'indoleamine 2,3-dioxygenase
WO2008036642A2 (fr) 2006-09-19 2008-03-27 Incyte Corporation N-hydroxyamidinohétérocycles en tant que modulateurs d'indoléamine 2,3-dioxygénase
WO2008036653A2 (fr) 2006-09-19 2008-03-27 Incyte Corporation N-hydroxyamidinohétérocycles modulateurs de l'indoléamine 2,3-dioxygénase
WO2008132601A1 (fr) 2007-04-30 2008-11-06 Immutep Anticorps monoclonal anti-lag-3 cytotoxique et son utilisation dans le traitement ou la prévention d'un rejet du greffon d'organe et de maladies auto-immunes
WO2009009116A2 (fr) 2007-07-12 2009-01-15 Tolerx, Inc. Thérapies combinées utilisant des molécules de liaison au gitr
WO2009044273A2 (fr) 2007-10-05 2009-04-09 Immutep Utilisation d'une protéine lag-3 recombinée ou de dérivés de celle-ci pour produire une réponse immunitaire des monocytes
WO2009073620A2 (fr) 2007-11-30 2009-06-11 Newlink Genetics Inhibiteurs de l'ido
WO2009156652A1 (fr) 2008-05-29 2009-12-30 Saint-Gobain Centre De Recherches Et D'etudes Europeen Structure en nid d'abeille a base de titanate d'aluminium
WO2010019570A2 (fr) 2008-08-11 2010-02-18 Medarex, Inc. Anticorps humains qui se lient au gène 3 d'activation des lymphocytes (lag-3), et leurs utilisations
WO2010077634A1 (fr) 2008-12-09 2010-07-08 Genentech, Inc. Anticorps anti-pd-l1 et leur utilisation pour améliorer la fonction des lymphocytes t
WO2011028683A1 (fr) 2009-09-03 2011-03-10 Schering Corporation Anticorps anti-gitr
WO2011056652A1 (fr) 2009-10-28 2011-05-12 Newlink Genetics Dérivés imidazole comme inhibiteurs de l'ido
WO2011070024A1 (fr) 2009-12-10 2011-06-16 F. Hoffmann-La Roche Ag Anticorps se liant de façon préférentielle au domaine extracellulaire 4 de csf1r humain et leur utilisation
WO2011109400A2 (fr) 2010-03-04 2011-09-09 Macrogenics,Inc. Anticorps réagissant avec b7-h3, fragments immunologiquement actifs associés et utilisations associées
WO2011107553A1 (fr) 2010-03-05 2011-09-09 F. Hoffmann-La Roche Ag Anticorps dirigés contre le csf-1r humain et utilisations associées
WO2011131407A1 (fr) 2010-03-05 2011-10-27 F. Hoffmann-La Roche Ag Anticorps contre le csf-1r humain et leurs utilisations
WO2011140249A2 (fr) 2010-05-04 2011-11-10 Five Prime Therapeutics, Inc. Anticorps liant csf1r
WO2012032433A1 (fr) 2010-09-09 2012-03-15 Pfizer Inc. Molécules de liaison 4-1bb
WO2012142237A1 (fr) 2011-04-15 2012-10-18 Newlink Geneticks Corporation Dérivés d'imidazole fusionnés pouvant être employés en tant qu'inhibiteurs d'ido
WO2012145493A1 (fr) 2011-04-20 2012-10-26 Amplimmune, Inc. Anticorps et autres molécules qui se lient à b7-h1 et à pd-1
WO2013079174A1 (fr) 2011-11-28 2013-06-06 Merck Patent Gmbh Anticorps anti-pd-l1 et utilisations associées
WO2013087699A1 (fr) 2011-12-15 2013-06-20 F. Hoffmann-La Roche Ag Anticorps contre le csf-1r humain et leurs utilisations
WO2013119716A1 (fr) 2012-02-06 2013-08-15 Genentech, Inc. Compositions et procédés d'utilisation d'inhibiteurs de csf1r
WO2013132044A1 (fr) 2012-03-08 2013-09-12 F. Hoffmann-La Roche Ag Thérapie combinée d'anticorps contre le csf -1r humain et ses utilisations
WO2013169264A1 (fr) 2012-05-11 2013-11-14 Five Prime Therapeutics, Inc. Méthodes destinées à traiter des affections avec des anticorps qui se lient au récepteur du facteur 1 de stimulation des colonies (csf1r)
WO2014008218A1 (fr) 2012-07-02 2014-01-09 Bristol-Myers Squibb Company Optimisation d'anticorps se liant à la protéine lag-3 exprimée par le gène 3 d'activation des lymphocytes, et leurs utilisations
WO2014036357A1 (fr) 2012-08-31 2014-03-06 Five Prime Therapeutics, Inc. Méthodes de traitement de pathologies par des anticorps qui se lient au récepteur du facteur stimulant les colonies 1 (csf1r)
WO2020132269A1 (fr) 2018-12-20 2020-06-25 KSQ Therapeutics, Inc. Pyrazolopyrimidines substituées et purines substituées et leur utilisation en tant qu'inhibiteurs de protéase 1 de traitement spécifique de l'ubiquitine
WO2021146378A1 (fr) * 2020-01-15 2021-07-22 KSQ Therapeutics, Inc. Compositions de pyrazolopyrimidines substituées et leurs utilisations
WO2022174184A1 (fr) * 2021-02-15 2022-08-18 Tango Therapeutics, Inc. Composés de pyrrolo[3,2-d]pyrimidine et méthodes d'utilisation dans le traitement du cancer
WO2022199652A1 (fr) * 2021-03-24 2022-09-29 Impact Therapeutics (Shanghai) , Inc Composés hétéroaryle-pyrimidine à cinq chaînons utilisés en tant qu'inhibiteurs d'usp1 et leur utilisation
WO2022216820A1 (fr) * 2021-04-07 2022-10-13 Forma Therapeutics, Inc. Inhibition de la protéase 1 spécifique de l'ubiquitine (usp1)
CN116496252A (zh) * 2022-04-29 2023-07-28 江苏亚虹医药科技股份有限公司 嘧啶类化合物、其制备方法及其医药用途
WO2024233605A1 (fr) * 2023-05-08 2024-11-14 Tango Therapeutics, Inc. Composés et leur utilisation contre le cancer

Patent Citations (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006029879A2 (fr) 2004-09-17 2006-03-23 F.Hoffmann-La Roche Ag Anticorps anti-ox40l
WO2006105021A2 (fr) 2005-03-25 2006-10-05 Tolerrx, Inc. Molecules de liaison gitr et leurs utilisations
WO2006122150A1 (fr) 2005-05-10 2006-11-16 Incyte Corporation Modulateurs de l'indolamine 2,3-dioxygenase et leurs procedes d'utilisation
WO2007005874A2 (fr) 2005-07-01 2007-01-11 Medarex, Inc. Anticorps monoclonaux humains diriges contre un ligand de mort programmee de type 1(pd-l1)
WO2007075598A2 (fr) 2005-12-20 2007-07-05 Incyte Corporation N-hydroxyamidinoheterocycles en tant que modulateurs d'indoleamine 2,3-dioxygenase
WO2008036642A2 (fr) 2006-09-19 2008-03-27 Incyte Corporation N-hydroxyamidinohétérocycles en tant que modulateurs d'indoléamine 2,3-dioxygénase
WO2008036653A2 (fr) 2006-09-19 2008-03-27 Incyte Corporation N-hydroxyamidinohétérocycles modulateurs de l'indoléamine 2,3-dioxygénase
WO2008132601A1 (fr) 2007-04-30 2008-11-06 Immutep Anticorps monoclonal anti-lag-3 cytotoxique et son utilisation dans le traitement ou la prévention d'un rejet du greffon d'organe et de maladies auto-immunes
WO2009009116A2 (fr) 2007-07-12 2009-01-15 Tolerx, Inc. Thérapies combinées utilisant des molécules de liaison au gitr
WO2009044273A2 (fr) 2007-10-05 2009-04-09 Immutep Utilisation d'une protéine lag-3 recombinée ou de dérivés de celle-ci pour produire une réponse immunitaire des monocytes
WO2009073620A2 (fr) 2007-11-30 2009-06-11 Newlink Genetics Inhibiteurs de l'ido
WO2009156652A1 (fr) 2008-05-29 2009-12-30 Saint-Gobain Centre De Recherches Et D'etudes Europeen Structure en nid d'abeille a base de titanate d'aluminium
WO2010019570A2 (fr) 2008-08-11 2010-02-18 Medarex, Inc. Anticorps humains qui se lient au gène 3 d'activation des lymphocytes (lag-3), et leurs utilisations
WO2010077634A1 (fr) 2008-12-09 2010-07-08 Genentech, Inc. Anticorps anti-pd-l1 et leur utilisation pour améliorer la fonction des lymphocytes t
WO2011028683A1 (fr) 2009-09-03 2011-03-10 Schering Corporation Anticorps anti-gitr
WO2011056652A1 (fr) 2009-10-28 2011-05-12 Newlink Genetics Dérivés imidazole comme inhibiteurs de l'ido
WO2011070024A1 (fr) 2009-12-10 2011-06-16 F. Hoffmann-La Roche Ag Anticorps se liant de façon préférentielle au domaine extracellulaire 4 de csf1r humain et leur utilisation
WO2011109400A2 (fr) 2010-03-04 2011-09-09 Macrogenics,Inc. Anticorps réagissant avec b7-h3, fragments immunologiquement actifs associés et utilisations associées
WO2011107553A1 (fr) 2010-03-05 2011-09-09 F. Hoffmann-La Roche Ag Anticorps dirigés contre le csf-1r humain et utilisations associées
WO2011131407A1 (fr) 2010-03-05 2011-10-27 F. Hoffmann-La Roche Ag Anticorps contre le csf-1r humain et leurs utilisations
WO2011140249A2 (fr) 2010-05-04 2011-11-10 Five Prime Therapeutics, Inc. Anticorps liant csf1r
WO2012032433A1 (fr) 2010-09-09 2012-03-15 Pfizer Inc. Molécules de liaison 4-1bb
WO2012142237A1 (fr) 2011-04-15 2012-10-18 Newlink Geneticks Corporation Dérivés d'imidazole fusionnés pouvant être employés en tant qu'inhibiteurs d'ido
WO2012145493A1 (fr) 2011-04-20 2012-10-26 Amplimmune, Inc. Anticorps et autres molécules qui se lient à b7-h1 et à pd-1
WO2013079174A1 (fr) 2011-11-28 2013-06-06 Merck Patent Gmbh Anticorps anti-pd-l1 et utilisations associées
WO2013087699A1 (fr) 2011-12-15 2013-06-20 F. Hoffmann-La Roche Ag Anticorps contre le csf-1r humain et leurs utilisations
WO2013119716A1 (fr) 2012-02-06 2013-08-15 Genentech, Inc. Compositions et procédés d'utilisation d'inhibiteurs de csf1r
WO2013132044A1 (fr) 2012-03-08 2013-09-12 F. Hoffmann-La Roche Ag Thérapie combinée d'anticorps contre le csf -1r humain et ses utilisations
WO2013169264A1 (fr) 2012-05-11 2013-11-14 Five Prime Therapeutics, Inc. Méthodes destinées à traiter des affections avec des anticorps qui se lient au récepteur du facteur 1 de stimulation des colonies (csf1r)
WO2014008218A1 (fr) 2012-07-02 2014-01-09 Bristol-Myers Squibb Company Optimisation d'anticorps se liant à la protéine lag-3 exprimée par le gène 3 d'activation des lymphocytes, et leurs utilisations
WO2014036357A1 (fr) 2012-08-31 2014-03-06 Five Prime Therapeutics, Inc. Méthodes de traitement de pathologies par des anticorps qui se lient au récepteur du facteur stimulant les colonies 1 (csf1r)
WO2020132269A1 (fr) 2018-12-20 2020-06-25 KSQ Therapeutics, Inc. Pyrazolopyrimidines substituées et purines substituées et leur utilisation en tant qu'inhibiteurs de protéase 1 de traitement spécifique de l'ubiquitine
WO2021146378A1 (fr) * 2020-01-15 2021-07-22 KSQ Therapeutics, Inc. Compositions de pyrazolopyrimidines substituées et leurs utilisations
WO2022174184A1 (fr) * 2021-02-15 2022-08-18 Tango Therapeutics, Inc. Composés de pyrrolo[3,2-d]pyrimidine et méthodes d'utilisation dans le traitement du cancer
WO2022199652A1 (fr) * 2021-03-24 2022-09-29 Impact Therapeutics (Shanghai) , Inc Composés hétéroaryle-pyrimidine à cinq chaînons utilisés en tant qu'inhibiteurs d'usp1 et leur utilisation
WO2022216820A1 (fr) * 2021-04-07 2022-10-13 Forma Therapeutics, Inc. Inhibition de la protéase 1 spécifique de l'ubiquitine (usp1)
CN116496252A (zh) * 2022-04-29 2023-07-28 江苏亚虹医药科技股份有限公司 嘧啶类化合物、其制备方法及其医药用途
WO2024233605A1 (fr) * 2023-05-08 2024-11-14 Tango Therapeutics, Inc. Composés et leur utilisation contre le cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Remington's Pharmaceutical Sciences", 1985
GREENEWUTS: "Protective Groups In Organic Synthesis", 1999, WILEY AND SONS
RAUTIO, J. ET AL., NATURE REVIEW DRUG DISCOVERY, vol. 17, 2018, pages 559 - 587

Similar Documents

Publication Publication Date Title
EP3154958B1 (fr) Inhibiteurs de phosphatidylinositol-3-kinase
EP3160960B1 (fr) Inhibiteurs de phosphatidylinositol 3-kinase
US11021467B2 (en) Phosphatidylinositol 3-kinase inhibitors
EP3154961B1 (fr) Dérivés de quinazolinone utilisés comme inhibiteurs de la phosphatidylinositol 3-kinase
EP3154969B1 (fr) Inhibiteur de la phosphatidylinositol 3-kinase
EP3154962B1 (fr) Inhibiteurs de la phosphatidylinositol 3-kinase
TW201737913A (zh) Tank－結合激酶抑制劑化合物
WO2018156901A1 (fr) Inhibiteurs de tyrosine kinase de bruton
WO2025096487A1 (fr) Composés de type protéase 1 spécifique de l'ubiquitine (usp1)
WO2025096490A1 (fr) Composés de type protéase 1 spécifique de l'ubiquitine (usp1)
WO2025096489A1 (fr) Composés relatifs à la protéase 1 spécifique de l'ubiquitine (usp1)
WO2025096494A1 (fr) Composés de protéase 1 de traitement spécifique de l'ubiquitine (usp1)
WO2025096539A1 (fr) Composés de protéase 1 de traitement spécifique de l'ubiquitine (usp1)
WO2025096488A1 (fr) Composés relatifs à la protéase 1 spécifique de l'ubiquitine (usp1)
WO2025096505A1 (fr) Composés de type protéase 1 spécifique de l'ubiquitine (usp1)
TW202535865A (zh) 泛素特異性加工蛋白酶1 (usp1) 化合物
CN120035593A (zh) 吡嗪衍生物及其用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24805682

Country of ref document: EP

Kind code of ref document: A1